Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAF237 versus glimepiride add-on to metformin in type 2 diabetes
2004-004559-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2005
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin add-on to metformin with Glimepiride add-on to metformin (2 arms). Primary endpoints: HbA1c, Risk of glycemic failure and 1 more. Started Jan 2005; status: completed.
02
Drugs
vildagliptinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-004559-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004559-21.